- Home
- CXAI vs INTS Comparison
CXAI vs INTS Comparison
Compare CXAI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- INTS
- Stock Information
- Founded
- CXAI N/A
- INTS 2012
- Country
- CXAI United States
- INTS United States
- Employees
- CXAI N/A
- INTS N/A
- Industry
- CXAI EDP Services
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- CXAI Technology
- INTS Health Care
- Exchange
- CXAI Nasdaq
- INTS Nasdaq
- Market Cap
- CXAI 22.4M
- INTS 9.4M
- IPO Year
- CXAI N/A
- INTS 2023
- Fundamental
- Price
- CXAI $1.09
- INTS $0.32
- Analyst Decision
- CXAI
- INTS Strong Buy
- Analyst Count
- CXAI 0
- INTS 3
- Target Price
- CXAI N/A
- INTS $8.50
- AVG Volume (30 Days)
- CXAI 440.9K
- INTS 2.6M
- Earning Date
- CXAI 08-11-2025
- INTS 08-07-2025
- Dividend Yield
- CXAI N/A
- INTS N/A
- EPS Growth
- CXAI N/A
- INTS N/A
- EPS
- CXAI N/A
- INTS N/A
- Revenue
- CXAI $6,548,000.00
- INTS N/A
- Revenue This Year
- CXAI N/A
- INTS N/A
- Revenue Next Year
- CXAI $60.00
- INTS N/A
- P/E Ratio
- CXAI N/A
- INTS N/A
- Revenue Growth
- CXAI N/A
- INTS N/A
- 52 Week Low
- CXAI $0.76
- INTS $0.26
- 52 Week High
- CXAI $3.76
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- CXAI 40.09
- INTS 37.08
- Support Level
- CXAI $0.87
- INTS $0.28
- Resistance Level
- CXAI $0.93
- INTS $0.32
- Average True Range (ATR)
- CXAI 0.04
- INTS 0.06
- MACD
- CXAI -0.01
- INTS 0.01
- Stochastic Oscillator
- CXAI 16.84
- INTS 7.43
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.